This study looked at the impacts of gene polymorphisms on Methotrexate in Chinese psoriasis patients.

Quote:

---

Background:
Methotrexate (MTX) is the first‐line treatment for psoriasis in China. The metabolic processes of MTX include various proteins and genes. Previous studies have shown that gene polymorphisms had significant impacts on the efficacy of MTX. However, the influence of gene polymorphisms has not been reported in the Chinese psoriatic patients.

Objective:
The aim of this study was to verify the impacts of candidate genes polymorphisms on the effectiveness of MTX in a Chinese psoriatic population.

Methods:
In this study, we enrolled 259 psoriasis patients from two clinical centres. Each of them received MTX treatment at 7.5‐15 mg/week for at least 8 weeks. Patients were stratified as responders and nonresponders according to whether the Psoriasis Area and Severity Index score declined more than 75% (PASI75). According to previous reports, 16 single‐nucleotide polymorphisms (SNPs) were selected and genotyped for each patient using the Sequenom platform. Fisher’s exact test, the χ2 test, Mann‐Whitney tests, and ANOVA analyses were used for statistical analysis.

Results:
Among 259 patients, there were 182 males and 77 females, 63 patients with psoriatic arthritis and 196 patients without arthritis phenotype, and the age of all patients ranged from 19 to 70 years (49.7±13.6). The baseline PASI value of patients was 13.8±8.5, and 33.2% of patients achieved a PASI75 response after MTX treatment. Patients carrying the ATP‐binding cassette subfamily B member 1 gene (ABCB1) rs1045642 TT genotype were associated with more severe psoriasis skin lesion (P=0.032). Furthermore, the ABCB1 rs1045642 TT genotype was found to be more frequent in nonresponders (P=0.017), especially in moderate‐to‐severe patients (P=0.002) and patients without psoriatic arthritis (P=0.026) after MTX treatment.

Conclusion:
We have demonstrated for the first time that polymorphism of the ABCB1 rs1045642 TT genotype is predictive of a worse clinical response of skin lesions to MTX therapy in a Chinese psoriatic population.

Source: onlinelibrary.wiley.com

*Early view funding unknown

Methotrexate

/cough Poison.

(Fri-10-04-2020, 22:10 PM)mataribot Wrote: /cough Poison.

Yep and should be removed from the list of treatments for psoriasis.

(Fri-10-04-2020, 22:19 PM)Fred Wrote:

(Fri-10-04-2020, 22:10 PM)mataribot Wrote: /cough Poison.

Yep and should be removed from the list of treatments for psoriasis.

Totally agreed with that. But on the contrary over here they are starting research on using MTX together with a biological with the purpose to prevent that your body makes antibodies to the biological, so that you can continue to use it for a longer time.

They had a survey online. I have filled it in and totally smashed MTX in my responses.

(Mon-13-04-2020, 07:17 AM)Caroline Wrote:

(Fri-10-04-2020, 22:19 PM)Fred Wrote:

(Fri-10-04-2020, 22:10 PM)mataribot Wrote: /cough Poison.

Yep and should be removed from the list of treatments for psoriasis.

Totally agreed with that. But on the contrary over here they are starting research on using MTX together with a biological with the purpose to prevent that your body makes antibodies to the biological, so that you can continue to use it for a longer time.

They had a survey online. I have filled it in and totally smashed MTX in my responses. 

They can stick that research as far as they can get it.